Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double-blind …
Background Erenumab was effective and well tolerated in a pivotal clinical trial of chronic
migraine. Here, we evaluated efficacy and safety of monthly erenumab (70 mg or 140 mg) …
migraine. Here, we evaluated efficacy and safety of monthly erenumab (70 mg or 140 mg) …
Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind …
M Ashina, S Tepper, JL Brandes, U Reuter… - … Journal of Headache, 2018 - europepmc.org
Background Erenumab was effective and well tolerated in a pivotal clinical trial of chronic
migraine. Here, we evaluated efficacy and safety of monthly erenumab (70 mg or 140 mg) …
migraine. Here, we evaluated efficacy and safety of monthly erenumab (70 mg or 140 mg) …
[PDF][PDF] Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double …
M Ashina, S Tepper, JL Brandes, U Reuter… - academia.edu
Background: Erenumab was effective and well tolerated in a pivotal clinical trial of chronic
migraine. Here, we evaluated efficacy and safety of monthly erenumab (70mg or 140mg) …
migraine. Here, we evaluated efficacy and safety of monthly erenumab (70mg or 140mg) …
Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind …
M Ashina, S Tepper, JL Brandes, U Reuter… - …, 2018 - research.regionh.dk
Background: Erenumab was effective and well tolerated in a pivotal clinical trial of chronic
migraine. Here, we evaluated efficacy and safety of monthly erenumab (70 mg or 140 mg) …
migraine. Here, we evaluated efficacy and safety of monthly erenumab (70 mg or 140 mg) …
Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind …
M Ashina, S Tepper, JL Brandes, U Reuter… - 2018 - pubmed.ncbi.nlm.nih.gov
Background Erenumab was effective and well tolerated in a pivotal clinical trial of chronic
migraine. Here, we evaluated efficacy and safety of monthly erenumab (70 mg or 140 mg) …
migraine. Here, we evaluated efficacy and safety of monthly erenumab (70 mg or 140 mg) …